Pharmacology News and Research

Latest Pharmacology News and Research

PKCiota oncogene essential for lung cancer stem cell proliferation

Scientists at the Mayo Clinic campus in Florida have found that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumors and are resistant to chemotherapy treatment.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Impact Fusion International completes geographic market test of Intact Digest

Impact Fusion International announced today it has successfully completed a limited geographic market test for Intact Digest with several retail vitamin stores re-ordering on a monthly basis.

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

LSU Professor awarded grant to support a Superfund Research Center

LSU Professor and Patrick F. Taylor Chair of Chemistry Barry Dellinger was recently awarded a grant of $3.6 million by the National Institute of Environmental Health Sciences, or NIEHS, to support a Superfund Research Center focusing on hazardous waste disposal and its impact on public health. It is the only center ever awarded by this program that is not located at a medical school or school of public health.

5 Sep 2009

Brain protein srGAP2 capable of forming filopodia

When the process goes awry, neurodevelopmental disorders such as mental retardation, dyslexia or autism may result. Researchers at the University of North Carolina at Chapel Hill School of Medicine have now discovered that establishing the neural wiring necessary to function normally depends on the ability of neurons to make finger-like projections of their membrane called filopodia.

5 Sep 2009

More youngsters are using anti-obesity drugs

Thousands of children and adolescents are using anti-obesity drugs that in the UK are only licensed for use by adults. The number of young people receiving prescriptions for these drugs has increased 15-fold since 1999, but most stop using them before they could expect to see any benefit, according to a new study.

3 Sep 2009

Biotransformed blueberry juice can function as anti-obesity and anti-diabetic agent

Juice extracted from North American lowbush blueberries, biotransformed with bacteria from the skin of the fruit, holds great promise as an anti-obesity and anti-diabetic agent. The study, published in the International Journal of Obesity, was conducted by researchers from the Universit- de Montr-al, the Institut Armand-Frappier and the Universit- de Moncton who tested the effects of biotransformed juices compared to regular blueberry drinks on mice.

2 Sep 2009

GS-101 effective in inhibiting and regressing corneal neovascularisation

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).

1 Sep 2009

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

1 Sep 2009

Clinical Healthcare Enterprise Framework to help healthcare HR for effective talent management

Salary.com, Inc. (NASDAQ: SLRY), a leading provider of on-demand compensation, payroll and talent management solutions, announced today that it has added the Clinical Healthcare Enterprise Framework to its growing Job Model and Competency Library of more than 1,200 job models and 1,300 functional competencies, which provide data and structure for typical jobs at all levels of an organization. The framework will enable healthcare HR professionals to create job roles easily, deliver job models quickly, and power their talent management systems.

1 Sep 2009

Elsevier publishes second edition of Signal Transduction

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announces the publication of the new second edition of Signal Transduction edited by Bastien D. Gomperts, Ijsbrand M. Kramer and Peter E.R. Tatham.

1 Sep 2009

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

Diagnostic HYBRIDS announced that the US Food and Drug Administration has cleared an additional claim for the company's D3 Ultra DFA Respiratory Virus Identification Kit, which confirms that the assay can detect the 2009 influenza A (H1N1)v virus.

31 Aug 2009

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists at Scripps Institution of Oceanography at UC San Diego and their colleagues at Creighton University have deciphered the highly unusual molecular structure of a naturally produced, ocean-based compound that is giving new understanding of the function of mammalian nerve cells.

29 Aug 2009

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease. They have been studying the impacts of nerve growth factors in the treatment of PD, and their latest results show that a certain growth factor can be used to halt the progress of damage brought on by a nerve poison and possibly even restore the function of damaged cells.

28 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Springer signs agreement with The Endocrine Society to co-publish a new journal

Springer, one of the leading publishers in the fields of science, technology and medicine, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010.

28 Aug 2009

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Anavex Life Sciences Corp. ("ANAVEX" or the "Company") reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

28 Aug 2009

Pharmacology News and Research

Latest Pharmacology News and Research

PKCiota oncogene essential for lung cancer stem cell proliferation

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Impact Fusion International completes geographic market test of Intact Digest

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

LSU Professor awarded grant to support a Superfund Research Center

Brain protein srGAP2 capable of forming filopodia

More youngsters are using anti-obesity drugs

Biotransformed blueberry juice can function as anti-obesity and anti-diabetic agent

GS-101 effective in inhibiting and regressing corneal neovascularisation

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Clinical Healthcare Enterprise Framework to help healthcare HR for effective talent management

Elsevier publishes second edition of Signal Transduction

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists study the impact of nerve growth factors for treating Parkinson's disease

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Springer signs agreement with The Endocrine Society to co-publish a new journal

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pharmacology News and Research

Latest Pharmacology News and Research

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in